WashU Medicine Discovers 'Backup' Immune Pathway That Could Make mRNA Cancer Vaccines More Effective

Researchers at Washington University School of Medicine in St. Louis, publishing in Nature (654: 485, 2026), described a previously unknown backup mechanism by which mRNA cancer vaccines activate tumor-fighting T cells. mRNA vaccines were thought to depend on a specific dendritic cell subset (cDC1) to present tumor antigens, but the team found that when cDC1 cells were absent in mouse models, a related subset (cDC2) stepped in via a process called 'cross-dressing' — outsourcing antigen production to other cells and then acquiring and displaying the resulting protein fragments to prime T cells. The finding suggests that deliberately engaging both the cDC1 and cDC2 pathways simultaneously could make mRNA cancer vaccines already in clinical trials — including personalized neoantigen candidates like mRNA-4157/V940 and BNT122 — substantially more effective, by widening and reinforcing the immune response beyond a single dendritic cell route.